The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate
- PMID: 28202319
- DOI: 10.1016/j.jsxm.2017.01.011
The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate
Abstract
Introduction: Postmenopausal women's knowledge about vulvar and vaginal atrophy (VVA) and available treatment options has historically been inadequate. Recent direct-to-consumer marketing and educational efforts would have been expected to increase awareness and treatment options.
Aim: To compare results of the Women's EMPOWER survey with other available VVA surveys to assess progress in women's understanding and approaches to treatment of VVA.
Methods: The Women's EMPOWER survey, an internet-based survey of US women with VVA symptoms, assessed women's awareness of VVA and their behaviors and attitudes associated with symptom treatment.
Main outcome measures: These survey results were compared with previously published results of the Revealing Vaginal Effects at Mid-Life (REVEAL), Women's Voices in Menopause (WVM), Vaginal Health: Insight, Views, & Attitudes (VIVA), Clarifying Vaginal Atrophy's Impact on Sex and Relationship (CLOSER), and Real Women's Views of Treatment Options for Menopausal Vaginal Changes (REVIVE) surveys.
Results: Results of the Women's EMPOWER survey were consistent with those of past VVA surveys and showed that postmenopausal women generally failed to recognize VVA and its chronic, progressive process and that they were reluctant to discuss vaginal or sexual symptoms with their health care professionals (HCPs). However, women indicated a strong desire for accurate medical information about VVA from their health care professionals and a willingness to learn if HCPs would initiate the conversation. Most women believed that vaginal symptoms are a normal part of aging and they just need to cope with the symptoms. In the United States, women were most concerned with safety-related issues, including increased risk of breast cancer, side effects, and systemic absorption.
Conclusion: The Women's EMPOWER survey demonstrates and reinforces that even with multimedia marketing and educational strategies in the years after other major VVA surveys, minimal progress has been made toward increasing women's awareness of, knowledge about, or understanding of VVA. Based on these data, a focus on initiating discussions and education with postmenopausal women so that they better comprehend VVA as a chronic progressive medical condition (not just aging), the symptoms associated with VVA, and the benefit-risk profile regarding treatment options is warranted. Krychman M, Graham S, Bernick B, et al. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med 2017;14:425-433.
Keywords: Attitudes; Knowledge; Menopause; Review; Survey; Vulvar and Vaginal Atrophy.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.J Sex Med. 2017 Mar;14(3):413-424. doi: 10.1016/j.jsxm.2017.01.010. Epub 2017 Feb 12. J Sex Med. 2017. PMID: 28202320
-
Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.J Sex Med. 2013 Jul;10(7):1790-9. doi: 10.1111/jsm.12190. Epub 2013 May 16. J Sex Med. 2013. PMID: 23679050
-
Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.Womens Health (Lond). 2014 Jul;10(4):445-54. doi: 10.2217/whe.14.29. Womens Health (Lond). 2014. PMID: 25259904 Review.
-
Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.Climacteric. 2016 Apr;19(2):188-97. doi: 10.3109/13697137.2015.1107039. Epub 2015 Nov 19. Climacteric. 2016. PMID: 26581580 Free PMC article.
-
Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.Expert Opin Drug Deliv. 2020 Nov;17(11):1573-1581. doi: 10.1080/17425247.2020.1810662. Epub 2020 Sep 2. Expert Opin Drug Deliv. 2020. PMID: 32877254 Review.
Cited by
-
Sexual function and distress in postmenopausal women with chronic insomnia: exploring the role of stress dysregulation.Nat Sci Sleep. 2019 Aug 22;11:141-153. doi: 10.2147/NSS.S213941. eCollection 2019. Nat Sci Sleep. 2019. PMID: 31686931 Free PMC article.
-
Comparison of the Efficacy of Vaginal Hyaluronic Acid to Estrogen for the Treatment of Vaginal Atrophy in Postmenopausal Women: A Systematic Review.Cureus. 2023 Aug 27;15(8):e44191. doi: 10.7759/cureus.44191. eCollection 2023 Aug. Cureus. 2023. PMID: 37767255 Free PMC article. Review.
-
Genitourinary Syndrome of Menopause.J Midlife Health. 2019 Jul-Sep;10(3):111-113. doi: 10.4103/jmh.JMH_125_19. J Midlife Health. 2019. PMID: 31579156 Free PMC article. No abstract available.
-
Genitourinary syndrome in menopause: Impact of vaginal symptoms.Turk J Obstet Gynecol. 2023 Mar 10;20(1):38-45. doi: 10.4274/tjod.galenos.2023.50449. Turk J Obstet Gynecol. 2023. PMID: 36908063 Free PMC article.
-
Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.Drugs Aging. 2019 Oct;36(10):897-908. doi: 10.1007/s40266-019-00700-w. Drugs Aging. 2019. PMID: 31452067 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous